Abstract
The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.
Keywords: COVID-19; Omicron; SARS-CoV-2; booster; clinical trial; neutralizing antibody; receptor-binding domain; subunit; vaccine; variant.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, Vaccine, clinical trial, omicron, Receptor-binding domain, booster, Variant., subunit, 【초록키워드】 coronavirus disease, Efficacy, coronavirus, vaccination, Vaccines, variant, variants, Protein, SARS-CoV-2 variants, symptomatic, vaccine candidate, Neutralizing, Breakthrough infection, booster dose, binding antibody, Support, acute respiratory syndrome, responses, caused, the receptor-binding domain, 【제목키워드】 coronavirus 2, respiratory, Level, Against,